OverviewSuggest Edit

Actinium Pharmaceuticals is a biopharmaceutical company developing targeted payload immunotherapeutics for the treatment of advanced cancers. Its targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. Actinium is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

TypePublic
Founded2000
HQNew York, US
Websiteactiniumpharma.com

Latest Updates

Employees (est.) (Feb 2019)25
Share Price (Mar 2019)$0.5 (-2%)

Key People/Management at Actinium Pharmaceuticals

Sandesh Seth

Sandesh Seth

Chief Executive Officer and Chairman of the Board
Mark Berger

Mark Berger

Chief Medical Officer
Dale L. Ludwig

Dale L. Ludwig

Chief Scientific Officer
Anil Kapur

Anil Kapur

Chief Commercial Officer
David Gould

David Gould

Senior Vice President, Corporate Development and Affairs
Vijay Reddy

Vijay Reddy

Vice President, Clinical Development
Show more

Actinium Pharmaceuticals Office Locations

Actinium Pharmaceuticals has an office in New York
New York, US (HQ)
275 Madison Ave
Show all (1)
Report incorrect company information

Actinium Pharmaceuticals Financials and Metrics

Actinium Pharmaceuticals Revenue

USD

Net income (FY, 2018)

(23.7m)

EBIT (FY, 2018)

(23.8m)

Market capitalization (22-Mar-2019)

59.9m

Closing stock price (22-Mar-2019)

0.5

Cash (31-Dec-2018)

13.7m

EV

46.5m
Actinium Pharmaceuticals's current market capitalization is $59.9 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

General and administrative expense

3.9m10.2m11.5m9.3m9.2m6.7m

R&D expense

12.3m

Operating expense total

6.6m22.4m24.8m26.8m26.9m23.8m

EBIT

(6.6m)(22.5m)(24.8m)(26.8m)(26.9m)(23.8m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

General and administrative expense

830.7k1.7m2.4m3.3m3.8m3.6m1.8m2.2m2.8m1.4m3.3m2.8m1.7m1.9m1.6m2.0m

R&D expense

4.5m

Operating expense total

1.6m4.1m4.4m7.0m7.9m7.4m4.6m6.0m6.9m7.1m7.8m7.2m6.7m6.4m4.9m6.2m

Depreciation and amortization

1.4k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

5.5m6.7m25.6m20.5m17.4m13.7m

Accounts Receivable

2.1b

Inventories

218.4k699.9k803.5k1.8m

Current Assets

5.8m7.4m26.5m22.4m17.8m14.3m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(10.8m)(24.7m)(21.0m)(24.3m)(26.6m)(23.7m)

Depreciation and Amortization

1.6k37.9k53.5k77.5k55.9k50.7k

Inventories

106.6k(193.9k)162.1k(1.0m)

Accounts Payable

(518.1k)(793.9k)2.7m405.2k1.1m
Quarterly
USDY, 2018

EV/EBIT

-2 x

EV/CFO

-2.3 x

Financial Leverage

1.7 x
Show all financial metrics
Report incorrect company information

Actinium Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Actinium Pharmaceuticals News and Updates

Actinium Pharmaceuticals CD33 Program to Focus on Actimab-MDS Pivotal Trial Enabling Study for Targeted Conditioning and Novel Combination Trials with Actimab-A and Venetoclax

NEW YORK, Oct. 30, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that the next stage of development for its CD33 ARC (Antibody Radiation Conjugate) Ac-225-Lintuzumab program, after successful completion of the Actimab-A phase 2 trial in Acute...

Actinium Pharmaceuticals to Hold Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update

NEW YORK, Oct. 26, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) will host a conference call and webinar today at 11:00 AM ET to provide key updates on the advancement of its CD33 program that is based on the Antibody RadiationConjugate (ARC), Ac-225 –...

Actinium Pharmaceuticals Announces Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update

NEW YORK, Oct. 22, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that it will host a conference call and webinar to provide key updates on the advancement of its CD33 program on Friday, October 26, 2018 at 11:00 AM ET. Actinium's CD33 program...
Report incorrect company information

Actinium Pharmaceuticals Blogs

Actinium Announces Update Including IP and New Data from Novel Combination of Actimab-A and Venetoclax Accepted for Poster Presentation at AACR Annual Meeting

- Poster supports rationale for recently initiated Phase 1/2 doublet clinical trial studying novel combination of Actimab-A and venetoclax and planned Phase 1/2 triplet combination trial of Actimab-A and venetoclax with a hypomethylating agent NEW YORK, March 20, 2019 /PRNewswire/ -- Actinium Pha…

Actinium Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Highlights

NEW YORK, March 19, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) reported its financial results for the fourth quarter and year ended December 31, 2018 as well as provided corporate and operational updates on clinical trials, research and development, recent hires,…

Actinium Pharmaceuticals to Present at the Oppenheimer & Co. 29th Annual Healthcare Conference

- Presentation scheduled for 1:35 pm ET on Wednesday, March 20th NEW YORK, March 15, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE American: ATNM) ("Actinium" or "the Company") announced today that it will present a corporate overview at the Oppenheimer & Co. 29th Annual Healthca…

Actinium's Late Breaking Oral Presentation at 2019 TCT Meetings Reports New Data on Donor Chimerism Indicating Deep Engraftment in All Iomab-B Treated Patients in the Pivotal Phase 3 SIERRA Trial

- All patients receiving Iomab-B achieved transplant engraftment and Donor Chimerism with 92% achieving Full Donor Chimerism prior to day 100 - SIERRA Trial is the only pivotal trial offering Bone Marrow Transplant as an option to patients with active, relapsed or refractory Acute Myeloid Leukemia a…

Actinium Highlights New Data at TCT Meetings Demonstrating Effective Lymphodepletion Supporting Iomab-ACT Program Development for Targeted Conditioning Prior to CAR-T and Adoptive Cell Therapy

- In vivo studies demonstrate CD45 targeting ARC effectively lymphodepletes, allowing cells to expand while sparing bone marrow stem cells, red blood cells and platelets - Targeted transient lymphodepletion achieved with non-myeloablative doses administered in a single infusion NEW YORK, Feb. 2…

Iomab-B One of Four Late Breaking Oral Presentations to be Presented at the 2019 Transplantation & Cellular Therapy Annual Meeting

- Iomab-B and multiple abstracts selected for inclusion at leading medical conference focused on bone marrow transplant and cellular therapy NEW YORK, Feb. 12, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE American: ATNM) announced today that a presentation of data from the pivotal P…
Show more

Actinium Pharmaceuticals Frequently Asked Questions

  • When was Actinium Pharmaceuticals founded?

    Actinium Pharmaceuticals was founded in 2000.

  • Who are Actinium Pharmaceuticals key executives?

    Actinium Pharmaceuticals's key executives are Sandesh Seth, Mark Berger and Dale L. Ludwig.

  • How many employees does Actinium Pharmaceuticals have?

    Actinium Pharmaceuticals has 25 employees.

  • Who are Actinium Pharmaceuticals competitors?

    Competitors of Actinium Pharmaceuticals include Egalet, Adaptive Biotechnologies and Cambridge Epigenetix.

  • Where is Actinium Pharmaceuticals headquarters?

    Actinium Pharmaceuticals headquarters is located at 275 Madison Ave, New York.

  • Where are Actinium Pharmaceuticals offices?

    Actinium Pharmaceuticals has an office in New York.

  • How many offices does Actinium Pharmaceuticals have?

    Actinium Pharmaceuticals has 1 office.